Philip S. Choi, Ph.D.

Partner, Registered Patent Attorney, Deputy Chair, Patent Prosecution Practice - Boston

Bio photo for Philip Choi
Download Media Photo

Contact Information

617.832.1743

617.832.7000

pchoi@foleyhoag.com Download vCard

Dr. Philip Choi has obtained numerous domestic and foreign patents for corporate, academic and independent research institutions in a wide range of technical areas, including the fields of biotechnology, biochemistry, materials science, biomedicine and pharmaceuticals. Philip specializes in helping academic institutions with cost-effective drafting and prosecution of pre-licensed patent applications, as well as representing institutional interests in the licensing and marketing of intellectual property available for technology transfer. In addition, he has extensive experience consulting on patent enforcement and litigation matters from discovery and deposition phases through to trial.

More ยป

Education:

  • Harvard University, Ph.D., Molecular and Cellular Biology
  • Boston University School of Law, J.D., cum laude
  • University of California Los Angeles, B.S., Molecular Cell and Developmental Biology, summa cum laude

Representative Experience

Representative list of patents obtained and patent applications drafted 

  • MHC Class II compounds generated by peptide exchange (U.S. Patent No. 8,314,210)
  • HIV infection treatment and prevention compositions (U.S. Patent Nos. 8,309,697 and 7,659,382)
  • Multiple myeloma diagnostic methods (U.S. Patent No. 8,211,634)
  • Activatable kinase libraries (U.S. Patent No. 8,178,317)
  • Methods for treating cancer using WHSC1L1 modulators and inhibitors (U.S. Patent No. 8,168,602)
  • Nucleic acid vaccines and methods of use thereof (U.S. Patent 8,128,922)
  • Gluconeogenesis- and thermogenesis-regulating compositions and methods (U.S. Patent Nos. 8,105,774; 7,371,529; 7,354,738; and 7,250,283)
  • Proteasome inhibitor-based cancer treatment methods (U.S. Patent No. 8,026,230)
  • Anti-tumor methods using immunogenicity enhancing bioengineered tumor cells (U.S. Patent No. 8,026,224)
  • Cell-based vaccines using fusion protein agents (U.S. Patent No. 8,007,781)
  • Huntington’s disease treatment methods (U.S. Patent No. 7,947,652)
  • Bioengineered tissue construct production methods (U.S. Patent No. 7,824,913)
  • Lymphoma-associated biomarkers (U.S. Patent Nos. 7,858,742 and 7,632,660)
  • Hematopoietic stem cell-based methods for upregulating immune responses (U.S. Patent No. 7,767,202)
  • Synthetic electroprocessed compositions and engineered tissues (U.S. Patent Nos. 7,759,082; 7,615,373; and 7,374,774)
  • PD-1 ligand interaction modulating methods (U.S. Patent Nos. 7,722,868 and 7,709,214)
  • Compound screening methods for identifying T cell activation and PD-1 signaling modulators (U.S. Patent Nos. 7,700,301 and 7,432,059)
  • Respiration uncoupling agent dosing methods for treating obesity (U.S. Patent No. 7,691,578)
  • B7 molecules for modulating immune responses (U.S. Patent Nos. 7,638,492 and 7,619,078)
  • Anti-B7-4 antibodies (U.S. Patent No. 7,635,757)
  • Anti-tumor methods using PPAR-gamma agonist compositions (U.S. Patent No. 7,635,708)
  • T cell apoptosis induction methods using anti-CTLA4 antibodies (U.S. Patent No. 7,592,007)
  • Genetically modified redox reaction enhancing prokaryotic cells (U.S. Patent No. 7,410,788)
  • Cochleate formulations comprising hydrophilic active pharmaceutical ingredients (International Patent Appl. Publ. No. WO 12/151517)
  • Ceramide-based cancer treatment methods (International International Patent Appl. Publ. No. WO 12/138739)
  • Chemokine receptor antagonist-based methods for treating cardiac and neurological disorders (International Patent Appl. Publ. No. WO 12/097062)
  • Devices and methods for treating heart failure using transient dyssynchrony (International Patent Appl. Publ. No. WO 12/064743)
  • Alphavirus infection inhibiting methods (International Patent Appl. Publ. No. WO 12/037485)
  • Global chromosomal aberration score assays and methods for predicting anti-cancer treatment efficacy (International Patent Appl. Publ. No. WO 12/027224)
  • Automated in situ contaminant detection system (U.S.  Patent Appl. Publ. No. 2012-0105830)
  • Methods of predicting anthracycline-based anti-cancer treatment efficacy (U.S. Patent Appl. Publ. No. 2012/0052079)
  • Stem cell-derived bioengineered constructs (U.S. Patent Appl. Publ. No 2011-0293667)
  • Cancer-associated biomarkers (International Patent Appl. Publ. Nos. WO11/091134; WO10/040124; and WO08/144724)
  • Galectin-1-based immune disorder treatments (International Patent Appl. Publ. Nos. WO11/060272; WO09/012384; and WO09/012382)
  • Pseudovirion-based methods for enhancing antigen-specific immune responses (International Patent Appl. Publ. No. WO11/017162)
  • Oncolytic virus-based methods for enhancing antigen-specific immune responses (International Patent Appl. Publ. No. WO10/129339
  • Brown fat cell differentiation activating methods (International Patent Appl. Publ. No. WO10/080985)
  • Hepatic disorder diagnostic, prognostic, and treatment methods (International Patent Appl. Publ. No. WO10/045470)
  • MicroRNA-based compositions and methods useful for diagnosing, prognosing, and treating inflammatory bowel diseases (International Patent Appl. Publ. No. WO09/120877)
  • Regulatable protein compositions (International Patent Appl. Publ. No. WO09/002607)
  • Tumor cell-based vaccines (U.S. Patent Appl. Publ. No. 2009/0285861)

Representative intellectual property-related litigation engagements

  • Counsel for the Dana-Farber Cancer Institute in five U.S. patent interferences related to PD-L1 immunomodulatory technology.
  • Technical lead for scientific matters in defense of an International Trade Commission investigation leading to invalidity of all asserted claims and unenforceability of an asserted patent (see Ajinomoto Co., Inc. v. ITC, 597 F.3d 1267 (2010)).
  • Litigation team member representing Becton Dickinson in a patent dispute with Gen-Probe involving methods of automating nucleic acid diagnostic assays.
  • Litigation team member representing Biogen Idec in a patent dispute with Sanofi-Aventis Deutschland involving human CMV regulatory sequence compositions.

Professional Experience

  • Teaching Fellow, Molecular Biology and Molecular Mechanisms of Gene Control, Harvard University
  • Choi P.S. et al. Members of the miRNA-200 Family Regulate Olfactory Neurogenesis. Neuron, 57(1):41-55 (2007)

Foley Hoag Alerts & Updates

Honors

  • Received Harvard University Certificate of Distinction in Teaching
  • Named National Science Foundation (NSF) Pre-Doctoral Fellow
  • Named UCLA Regents Scholar (Full-Tuition Scholarship)
  • Named Howard Hughes Medical Institute Undergraduate Researcher

Involvement

  • Pro bono work to secure patent rights and provide intellectual property advice for a non-profit marine research laboratory
  • Boston Patent Law Association, Member
  • Association of University Technology Managers, Member
Add to Bio Folder

Download Bio

Bar Admissions

  • Massachusetts

Court Admissions

  • U.S. Patent & Trademark Office (Agency)